As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.
News|Articles|March 13, 2024
COVID-19 Never Truly Goes Away: Long COVID’s Debilitating Symptoms Uproots Lives
Author(s)Chelsie Derman
Now, 4 years since the start of the pandemic, how has sleep been impacted? Sleep experts provide their perspective.
Advertisement
Advertisement
Before Liza Fisher contracted the COVID-19 virus, she worked as a flight attendant, drove, and went to the grocery store with ease. All that came to a halt after the virus entered her body in early 2020. Like many others, she was quarantined, unable to see friends or family.
Related to this article
Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.
Advertisement
Advertisement